

ESGO2011
Milano



Gynecologic Cancer Trials in Asia

Keiichi Fujiwara, MD, PhD
Department of Gynecologic Oncology
Saitama Medical University
International Medical Center

Gyn Cancer Clinical Trials in Asia

- Trials using new agents are RARE.
- Combination of existing drugs
- Route of giving drugs
- Timing of chemotherapy
- How radiation should be delivered
- etc.....

CERVICAL CANCER TRIALS IN ASIA

Cervical Cancer Trials in Asia

- KCOG1008/GOG263
- TACO:GCIG/KGOG1027
- KGOG-1029
- JGOG DT-101
- JGOG DT-104
- JCOG0505
- GOTIC-002

GOG 263/KGOG 1008: Randomized Phase III Clinical Trial of Adjuvant Radiation vs Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Cervical cancer

Stage I-IIA

Radical hysterectomy+BPLND
≥2 of intermediate risk factors

Randomization

Control Arm; Radiation therapy

CRT Arm; Weekly CDDP
40mg/m² concurrent to radiation

TACO: GCIG/KGOG1027

Weekly versus Tri-weekly Cisplatin based Chemoradiation

Cervical cancer


Locally advanced cervical
cancer
Stage IIB-IVA

Randomization

Control Arm; Weekly Cisplatin
40mg/m² 6 cycles

Study Arm; Tri-weekly Cisplatin
75mg/m² 3 cycles

A Randomized controlled trial comparing *radical hysterectomy plus tailored adjuvant therapy* versus *primary chemoradiation therapy* in bulky early-stage cervical cancer



Objectives

- **Primary endpoint**
 - To compare *overall survival* between ***RH + tailored Adj Tx*** and ***CCRT***
- **Secondary endpoint**
 - To compare *disease-free survival, early & late toxicity, & quality of life* between ***RH + tailored Adj Tx*** and ***CCRT***


Inclusion Criteria

- FIGO stage IB and IIA cervical cancer
- Tumor size > 4 cm in MRI
(regardless of LN enlargement & Subtle PM involvement)
- Histologic types
Squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma
- Age: 20-75 years
- ECOG Performance status: 0-2
- Adequate organ functions: BM, Kidney, Liver
- Written informed consent



JGOG DT-101

CCRT +/- Immunomodulator Z-100



Enrollment: 249 Patients between September 2004-October 2006
CCRT 75%

JGOG DT-101

Phase III Study of **S-1** + Cisplatin compared with single-agent Cisplatin in stage IVB, recurrent, or persistent carcinoma of the cervix


S-1 is a oral agent with combination of tegafur, uracil, and gimeracil. This agent has been approved as TS-1 in Japan, and recently approved as Teysono by EMEA for advanced gastric cancer.

JGOG DT-104

Study Design

- Primary endpoint: OS

Stage IVB, recurrent or persistent cervical cancer



Stratification factor:

- Presence or Absence of lesion in previously irradiated field
- Previous history of platinum containing drug (yes or no)
- Institution

* Crossover treatment of S-1 after the disease progression in patients who are assigned to single-agent Cisplatin arm will be prohibited

Final patient enrollment status


Japan&Taiwan: 100%
(222 + 48 = 270 / 260 pts)

Korea: 100% (105 / 100 pts)

Total : 100% (375 / 360 pts)

Arm SP: 189pts(not treated: 1pts)

Arm P: 186pts(not treated: 10pts)



JCOG0505

Stage IVb or Recurrent
Cervical Cancer
Not Indicated for local
therapy
No prior taxen
20-75 yo, PS 0-2




TP

Paclitaxel 135 mg/m²/24hr div day1
Cisplatin 50 mg/m²/2hr div day2


TC

Paclitaxel 175 mg/m²/3hr div day1
Carboplatin AUC 5/1 hr div

Primary Endpoint: OS
Target Accrual 250
Enrolled 253



GOTIC-002



UFT:

Oral agent which contains tegafur and uracil.

Active against multiple cancer such as cervix, lung, breast or colorectal.

Positive phase III result after surgery for colon, lung and breast.

OVARIAN CANCER TRIALS IN ASIA

Ovarian Cancer Trials in Asia

- JGOG3016
- JGOG3019 iPocc Trial
- JGOG3017/GCIG
- JCOG0602
- AGO OVAR-16/GCIG (KGOG, JGOG)

Schema of JGOG 3016

**Ovarian Epithelial, Primary Peritoneal,
or Fallopian Tube cancer**
FIGO Stage II-IV



Randomization

Stratification;

Residual disease: $\leq 1\text{cm}$, $> 1\text{cm}$

FIGO Stage: II vs. III vs. IV

Histology: clear cell/mucinous vs. serous/others




Conventional TC (c-TC)

Paclitaxel $180\text{mg}/\text{m}^2$, day 1
Carboplatin AUC 6.0, day 1
every 21 days for 6-9 cycles

Dose-dense weekly TC (dd-TC)


Paclitaxel $80\text{mg}/\text{m}^2$, days 1,8,15
Carboplatin AUC 6.0, day 1
every 21 days for 6-9 cycles

Progression-Free Survival



Treatment	n	Event	Median PFS	P value	HR	95%CI
c-TC	319	200	17.2 mos.			
dd-TC	312	160	28.0 mos.	0.0015	0.714	0.581-0.879

Overall Survival



Treatment	n	Event	3-yr survival	P value	HR	95%CI
c-TC	319	124	65.1%			
dd-TC	312	96	72.1%	0.0325	0.749	0.574-0.976



International Cooperative Phase III Study for Clear Cell Carcinoma



-Clear Cell Ca
-Stage I - IV

RANDOMIZATION

TC

Paclitaxel 175 mg/m² (d1)
Carboplatin AUC 6 (d1)
Every 3 wk x 6

Irinotecan/CDDP

CPT-11 60 mg/m² (d1, 8, 15)
Cisplatin 60 mg/m² (d1)
Every 4 wk x 6

Closed for accrual

Japan 623


Korea 25

France 12

UK 7


Opened Sep 2006

Closed May 2011



IntraPeritoneal therapy for Ovarian Cancer with Carboplatin
(GOTIC-001 / JGOG3019)

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin
in Combination with Intravenous Weekly Dose-Dense Paclitaxel
for Newly Diagnosed Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer



Primary Endpoint: PFS


Secondary Endpoint: OS, Toxicity, QOL

Accrual : 44 / 746 patents


Austria, Australia, Korea, Singapore will be on board

JCOG0602 Trial

Stage III/IV
Ovarian, FT, Perit
Confirmed by
CT/MRI
Cytology from Fluid



Primary Endpoint: OS
Target Accrual: 300
Started November 17/ 2006
One patient to go



Other Ovarian Cancer Trials

- Platinum Sensitive (Random Phase II)
 - Gemcitabine + Carbo vs Paclitaxel + Carbo (KGOG)
 - Gemcitabine + Carbo vs PLD + Carbo (GOTIC)
- Platinum Resistant
 - PLD 50 mg/m² vs 40 mg/m² (P III, JGOG)
 - Etoposide + Irinotecan (P II, JCOG)

ENDOMETRIAL CANCER TRIALS IN ASIA

Endometrial Cancer
THA, BSO, PLNx
Stage I-II
MI>1/2, G2-3 or ser or ccc
Stage III
Stage IV without distant
metastasis


R

AP x6 cycles
Adriamycin 60 mg/m²
Cisplatin 50 mg/m²

DP x6 cycles
Docetaxel 70 mg/m²
Cisplatin 60 mg/m²

TC x6 cycles
Paclitaxel 180 mg/m²/3hr div day1
Carboplatin AUC 6 div

Primary Endpoint PFS
Accrual 788/780
Opened October 2006
Closed December 2010



Gyn Cancer Trials in Asia

- Unique approach
- Growing Economy will increase the new drug development in the near future
- Asian Collaboration as well as Global Collaboration will enhance the establishment of new evidences.